Clearstone Central Laboratories, a provider of central laboratory services for late-stage clinical trials, announced today a global collaboration with Laboratory Corporation of America® Holdings (LabCorp®) through its Esoterix Clinical Trials Services division, providing clients with seamless access to CAP-accredited laboratories across both organizations in Belgium, Canada, China, France, Singapore and the United States. This global collaboration will deliver expert safety, diagnostic and specialty testing services in support of drug development and clinical trials. In addition, clients of each company will be able to access LabCorp’s industry-leading assay portfolio and Clearstone’s state-of-the-art central laboratory protocol management system APOLLO CLPM(TM).
“We are very pleased to announce this strategic collaboration with LabCorp because of the value it creates for our clients”, said Clearstone CEO Lewis Cameron. “LabCorp is well established in the diagnostic and clinical trials markets. This global collaboration provides LabCorp with an expanded international presence to serve the global clinical trials market. Clearstone’s clients will have access to the largest combined assay portfolio in the industry, with much greater specialty and biomarker testing capabilities. More so, our collaboration creates one of the most advanced scientific portfolios in the central lab market with globally harmonized and state-of-the-art testing platforms in areas such as pharmacogenomics, microbiology, immunohistochemistry, allergy testing, cytogenetics and flow cytometry.”
